Inhibrx Biosciences (INBX) Other Non-Current Assets (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Other Non-Current Assets data on file, last reported at $4.4 million in Q4 2025.

• Other Non-Current Assets for Q4 2025 came in at $4.4 million, down 35.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.4 million (down 35.91% YoY), and the FY2025 annual result was $4.4 million, down 35.91% from the prior year.
• Other Non-Current Assets declined to $4.4 million in Q4 2025 per INBX's latest filing, from $5.7 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $6.8 million in Q4 2024 and troughed at $3.2 million in Q4 2023.
• A 3-year average of $5.9 million and a median of $6.7 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 115.9% in 2024, then sank 35.91% in 2025.
• A 3-year view of Other Non-Current Assets shows it stood at $3.2 million in 2023, then jumped by 115.9% to $6.8 million in 2024, then plunged by 35.91% to $4.4 million in 2025.
• Business Quant data shows INBX's Other Non-Current Assets at $4.4 million in Q4 2025, $5.7 million in Q3 2025, and $6.8 million in Q2 2025.